Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase.

The abuse of antibacterial drugs imposes a selection pressure on bacteria that has driven the evolution of multidrug resistance in many pathogens. Our efforts to discover novel classes of antibiotics to combat these pathogens resulted in the discovery of amycolamicin (AMM). The absolute structure of AMM was determined by NMR spectroscopy, X-ray analysis, chemical degradation, and modification of its functional groups. AMM consists of trans-decalin, tetramic acid, two unusual sugars (amycolose and amykitanose), and dichloropyrrole carboxylic acid. The pyranose ring named as amykitanose undergoes anomerization in methanol. AMM is a potent and broad-spectrum antibiotic against Gram-positive pathogenic bacteria by inhibiting DNA gyrase and bacterial topoisomerase IV. The target of AMM has been proved to be the DNA gyrase B subunit and its binding mode to DNA gyrase is different from those of novobiocin and coumermycin, the known DNA gyrase inhibitors.

[1]  W. Ko,et al.  Characterizations of Clinical Isolates of Clostridium difficile by Toxin Genotypes and by Susceptibility to 12 Antimicrobial Agents, Including Fidaxomicin (OPT-80) and Rifaximin: a Multicenter Study in Taiwan , 2012, Antimicrobial Agents and Chemotherapy.

[2]  G. Basarab,et al.  Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy. , 2011, Bioorganic & medicinal chemistry letters.

[3]  Scott K. Smith,et al.  Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. , 2011, Chemistry & biology.

[4]  Ryuichi Sawa,et al.  Tripropeptin C Blocks the Lipid Cycle of Cell Wall Biosynthesis by Complex Formation with Undecaprenyl Pyrophosphate , 2011, Antimicrobial Agents and Chemotherapy.

[5]  H. Endeman,et al.  Therapy in pneumonia: what is beyond antibiotics? , 2011, The Netherlands journal of medicine.

[6]  L. Saravolatz,et al.  In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). , 2010, International journal of antimicrobial agents.

[7]  M. Igarashi,et al.  Biological activities of pargamicin A, a novel cyclic peptide antibiotic from Amycolatopsis sp. , 2010, The Journal of Antibiotics.

[8]  Yoshikazu Takahashi,et al.  Biosynthesis of amycolamicin: the biosynthetic origin of a branched α-aminoethyl moiety in the unusual sugar amycolose , 2010, The Journal of Antibiotics.

[9]  S. Bae,et al.  Antimicrobial Resistance in Haemophilus influenzae Respiratory Tract Isolates in Korea: Results of a Nationwide Acute Respiratory Infections Surveillance , 2009, Antimicrobial Agents and Chemotherapy.

[10]  P. Charifson,et al.  Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds , 2006, Antimicrobial Agents and Chemotherapy.

[11]  Naoko Chiba,et al.  Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. , 2005, The Journal of antimicrobial chemotherapy.

[12]  T. Nishino,et al.  Accumulation of Mutations in both gyrB and parE Genes Is Associated with High-Level Resistance to Novobiocin in Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[13]  A. Sundsfjord,et al.  Molecular Epidemiology of Macrolide-Resistant Isolates of Streptococcus pneumoniae Collected from Blood and Respiratory Specimens in Norway , 2005, Journal of Clinical Microbiology.

[14]  H. Grundmann,et al.  Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. , 2004, The Journal of antimicrobial chemotherapy.

[15]  J. Mcgowan,et al.  In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. , 2003, Microbial drug resistance.

[16]  Fred C Tenover,et al.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. , 2003, The New England journal of medicine.

[17]  N. Matsumori,et al.  Absolute configuration of aflastatin A, a specific inhibitor of aflatoxin production by Aspergillus parasiticus. , 2000, The Journal of organic chemistry.

[18]  H. Naganawa,et al.  Decatromicins A and B, new antibiotics produced by Actinomadura sp. MK73-NF4. II. Structure determination. , 1999, The Journal of antibiotics.

[19]  K. Harada,et al.  A Nonempirical Method Using LC/MS for Determination of the Absolute Configuration of Constituent Amino Acids in a Peptide: Combination of Marfey's Method with Mass Spectrometry and Its Practical Application , 1997 .

[20]  J. Clardy,et al.  Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp. C39217-R109-7. II. Isolation, physico-chemical properties, spectroscopic study and X-ray analysis. , 1996, The Journal of antibiotics.

[21]  B. J. Royles.  NATURALLY OCCURRING TETRAMIC ACIDS : STRUCTURE, ISOLATION, AND SYNTHESIS , 1995 .

[22]  D. H. Jones.  PCR mutagenesis and recombination in vivo. , 1994, PCR methods and applications.

[23]  G. Silverman.  Isolating vector-insert junctions from yeast artificial chromosomes. , 1993, PCR methods and applications.

[24]  S. Schenk,et al.  Improved method for electroporation of Staphylococcus aureus. , 1992, FEMS microbiology letters.

[25]  T. Kusumi,et al.  High-field FT NMR application of Mosher's method. The absolute configurations of marine terpenoids , 1991 .

[26]  T. Takeuchi,et al.  Syntheses and antitumor activities of 7-O-(6-deoxy-2-O-methyl-alpha-L-talopyranosyl)-daunomycinone and -adriamycinone. , 1989, The Journal of antibiotics.

[27]  J. Duval,et al.  Transferable vancomycin and teicoplanin resistance in Enterococcus faecium , 1989, Antimicrobial Agents and Chemotherapy.

[28]  H. Umezawa,et al.  Synthesis of antitumor-active 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)-daunomycinone and -adriamycinone. , 1987, Carbohydrate research.

[29]  I. Hayakawa,et al.  Synthesis and antibacterial activities of optically active ofloxacin , 1986, Antimicrobial Agents and Chemotherapy.

[30]  M. Lechevalier,et al.  Two New Genera of Nocardioform Actinomycetes: Amycolata gen. nov. and Amycolatopsis gen. nov. , 1986 .

[31]  R. Fass.  In vitro activity of ciprofloxacin (Bay o 9867) , 1983, Antimicrobial Agents and Chemotherapy.

[32]  P. Wessels,et al.  Tautomerism in tetramic acids: 13C nmr determination of the structures and ratios of the tautomers in 3-acetyl-5-isopropylpyrrolidine-2,4-dione , 1978 .

[33]  H. Isbell,et al.  Mutarotation, Hydrolysis, and Rearrangement Reactions of Glycosylamines1 , 1958 .